In collaboration with four prestigious neurologists, Pivotal has begun screening patients for the Phase I research effort, which is expected to have major implications for the treatment of Alzheimer patients... Pioneer Behavioral Health's Press Release -
Blog Archive
-
▼
2008
(79)
-
▼
April
(15)
- AstraZeneca and Washington University In St. Louis...
- Baxter : Study Results of GAMMAGARD S/D and GAMMAG...
- Medivation : Dimebon Improves Significantly Think...
- Lexicon : Clinical Data for LX6171, a Drug Candida...
- Intellect Neurosciences : ... Grant Requirements f...
- Allon at BIO Europe Partnering Meeting
- PerkinElmer : New Innovations to Strengthen Drug D...
- Exelgen : Two New Major Drug Discovery Collaborat...
- Satoris : Collaboration to Validate Early Alzheime...
- PHC Pioneer Behavioral Health : Phase I Alzheimer'...
- Pharmathene : Recombinant Butyrylcholinesterase (r...
- QuantRx , FluoroPharma : Technology Platform to I...
- Memory Pharmaceuticals : Advance Development and C...
- EPIX Pharmaceuticals : Phase 2a Alzheimer's Data a...
- Lilly : First Phase III Trial for Treatment of Alz...
-
▼
April
(15)
Friday, April 11, 2008
PHC Pioneer Behavioral Health : Phase I Alzheimer's Disease Trial to Date for Major National Sponsor
Apr 10, 2008 - PHC, Inc. (AMEX: PHC) d.b.a. Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services and pharmaceutical research, reported that its Pivotal Research Centers has initiated its largest Phase I Alzheimer's Disease trial to date for a major national sponsor.